Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Neurological Disorder Diagnostics Market– Market Insights

Neurological disorder diagnostics tools are medical devices that are used for diagnosing various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices, which are majorly used in diagnosis include imaging tools such as computed tomography (CT), magnetic resonance imaging (MRI), and in vitro diagnostic tools such as biomarkers and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic tools. For instance, according to data published by Alzheimer’s Association in 2018, around 5.7 million people in the U.S. of all age groups suffered from Alzheimer’s and dementia in 2017.

Furthermore, various private and government organizations are taking initiatives to raise awareness about neurological disorders by providing knowledge of diagnosis and treatment about neurological disorders, which is expected to drive the market growth. For instance, in 2012, Georgetown University Medical Center in collaboration with MedStar Georgetown University Hospital, established Huntington Disease Care, Education, and Research Center that offers diagnosis, treatment, and patient education for Huntington’s disease.

The global neurological disorder diagnostics market size is expected to be valued at US$ 12,162.6 million in 2019 and is expected to exhibit a CAGR of 7.6% over the forecast period (2019–2027).

Figure 1. Global Neurological Disorder Diagnostics Market Value (US$ Mn), by Region, 2019

Neurological Disorder Diagnostics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing number of approvals and launches of novel diagnostic tools

In the recent past, several key players in the market have received approval for launching novel diagnostic tools. Moreover, approval and launch of such novel tools in the market is expected to create lucrative environment for the global neurological disorder diagnostics market growth over the forecast period. For instance, in April 2018, Canon Medical Systems received 510 (k) clearance from the U.S. Food and Drug Administration for its new Aquilion Precision (CT) scanner. Aquilion Precision is an ultra-high resolution CT system (UHR CT).

Moreover, in March 2018, Koninklijke Philips N.V. launched its new 3-tesla MRI scanner, Elition 3.0T. This new MRI scanner reduces scanning time by 50%, which is expected to enhance patient experience. Furthermore, in January 2019, Canon Medical Systems Corporation launched Aquilion Start CT system with 16 and 32 slice configurations suitable for institutions aspiring to make diagnostic CT imaging more accessible and affordable.

However, high cost of diagnostic tools such as MRI machines and CT scan is a major factor, which is expected to hinder growth of global neurological disorder diagnostics market in emerging economies such as India, and China. According to American Health Imaging, price of a magnetic resonance imaging (MRI) devices starts from US$ 150,000, and a high end device costs more than US$ 1 million. Such high cost devices are only adopted by big hospitals and diagnostic laboratories.

Figure 2. Global Neurological Disorder Diagnostics Market Share (%), by Disease Indication

Neurological Disorder Diagnostics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing strategic collaborations for development of new diagnostic tools is expected to propel the market growth

Strategic collaborations among key players are expected to fuel growth of the global neurological disorder diagnosis market over the forecast period. For instance, in March 2018, Canon Medical Systems, Kumamoto University, and University of Bordeaux entered into a collaborative research for the development of deep learning technology in magnetic resonance imaging.

Moreover, in 2017, Singapore-based National Neuroscience Institute and Nanyang Technological University (NTU Singapore) collaborated to develop novel and innovative technologies for better diagnosis and treatment of patients with neurological conditions such as Parkinson’s disease, and brain injuries.

Furthermore, in January 2017, Siemens Healthineers and Biogen signed an agreement to develop new MRI tools for multiple sclerosis.

Key Players

Major players operating in the global neurological disorder diagnostics market include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation

Neurological disorder diagnostic tools are used for the diagnosis of various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and others. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostic techniques. Imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels, and other parts of body. Whereas, in-vitro diagnostic techniques include biopsy, biomarker, blood test, urine test, and genetic testing.

Market Dynamics

Technological innovations and developments in neurological disorder diagnosing devices are expected to drive the market growth. For instance, in 2017, Neusoft Medical Systems developed an innovative CT scanner NeuViz Prime CT Scanner and received the U.S. Food and Drug Administration approval for the system. Moreover in 2016, Koninklijke Philips N.V. launched IQon Spectral CT in Canada. IQon Spectral CT is a spectral detector CT, designed specifically for spectral imaging.

Key features of the study:

  • This report provides in-depth analysis of the global neurological disorder diagnostics market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global neurological disorder diagnostics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
  • The global neurological disorder diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurological disorder diagnostics market

Detailed Segmentation:

  • Global Neurological Disorder Diagnostics Market, By Technology:
    • Imaging
      • Computed Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
      • Nuclear Medicine Imaging
      • Positron Emission Tomography (PET)
      • Single-photon Emission Computed Tomography (SPECT)
      • Near Infrared Spectroscopic Imaging (NIRS)
      • Electroencephalography (EEG)
      • Magnetoencephalography (MEG)
    • In Vitro Diagnostics
      • Biomarker
      • Biopsy
      • Others
  • Global Neurological Disorder Diagnostics Market, By Disease Indication:
    • Genetic Neurological Disorders
      • Alzheimer’s Disease (AD)
      • Parkinson’s Disease (PD)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Huntington's Disease (HD)
      • Others
    • Immunological Neurological Disorders
      • Multiple Sclerosis
      • Others
    • Paraneoplastic Syndrome
    • Paraproteinemic Neuropathies
    • Others
  • Global Neurological Disorder Diagnostics Market, By End User:
    • Hospitals & Clinics
    • Diagnostic Centers
    • Ambulatory Care Centers
  • Global Neurological Disorder Diagnostics Market, By Region:
    • North America
      • By Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic Neuropathies
        • Others
      • By End User:
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic Neuropathies
        • Others
      • By End User:
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic Neuropathies
        • Others
      • By End User:
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Rest of Europe
    • Asia Pacific
      • By Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic Neuropathies
        • Others
      • By End User:
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic Neuropathies
        • Others
      • By End User:
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Technology:
        • Imaging
          • Computed Tomography (CT)
          • Magnetic Resonance Imaging (MRI)
          • Nuclear Medicine Imaging
          • Positron Emission Tomography (PET)
          • Single-photon Emission Computed Tomography (SPECT)
          • Near Infrared Spectroscopic Imaging (NIRS)
          • Electroencephalography (EEG)
          • Magnetoencephalography (MEG)
        • In Vitro Diagnostics
          • Biomarker
          • Biopsy
          • Others
      • By Disease Indication:
        • Genetic Neurological Disorders
          • Alzheimer’s Disease (AD)
          • Parkinson’s Disease (PD)
          • Amyotrophic Lateral Sclerosis (ALS)
          • Huntington's Disease (HD)
          • Others
        • Immunological Neurological Disorders
          • Multiple Sclerosis
          • Others
        • Paraneoplastic Syndrome
        • Paraproteinemic Neuropathies
        • Others
      • By End User:
        • Hospitals & Clinics
        • Diagnostic Centers
        • Ambulatory Care Centers
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Siemens Healthineers *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
    • Koninklijke Philips N.V.
    • General Electric Company
    • Esaote SpA
    • NeuroLogica Corporation
    • Masimo Corporation
    • York Instruments Ltd
    • Neusoft Medical Systems
    • Canon Medical Systems Corporation

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Technology
      • Market Snippet, By Disease Indication
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • Merger and Acquisition Scenario
    • PEST Analysis
  4. Global Neurological Disorder Diagnostics Market, By Technology, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Imaging
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Computed Tomography (CT)
        • Magnetic Resonance Imaging (MRI)
        • Nuclear Medicine Imaging
        • Positron Emission Tomography (PET)
        • Single-photon Emission Computed Tomography (SPECT)
        • Near Infrared Spectroscopic Imaging (NIRS)
        • Electroencephalography (EEG)
        • Magnetoencephalography (MEG)
    • In Vitro Diagnostics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Biomarker
        • Biopsy
        • Others
  5. Global Neurological Disorder Diagnostics Market, By Disease Indication, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Genetic Neurological Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Alzheimer’s Disease (AD)
        • Parkinson’s Disease (PD)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Huntington's Disease (HD)
        • Others
    • Immunological Neurological Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Multiple Sclerosis
        • Others
    • Paraneoplastic Syndrome
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Paraproteinemic Neuropathies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Neurological Disorder Diagnostics Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Diagnostic Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ambulatory Care Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Neurological Disorder Diagnostics Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Technology, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
      • Latin America
        • Market Size and Forecast, By Technology, 2016 – 2027, (US$ Mn)
        • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
        • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
        • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
          • Brazil
          • Mexico
          • Argentina
          • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Technology, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Technology, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Technology, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Technology, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Siemens Healthineers
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Koninklijke Philips N.V.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • General Electric Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Esaote SpA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NeuroLogica Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Masimo Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • York Instruments Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Neusoft Medical Systems
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Canon Medical Systems Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 36 market data tables and 30 figures on "Neurological Disorder Diagnostics Market” - Global forecast to 2027.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner